Total planned funding: $430,446,343
Clear active filters
University
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
Allocations
Countries/Regions
Kenya | $64,965,326 |
Ethiopia | $60,775,977 |
Tanzania | $54,948,002 |
Mozambique | $48,500,687 |
South Africa | $38,820,320 |
Uganda | $33,164,514 |
Malawi | $19,303,471 |
Haiti | $14,225,000 |
Botswana | $12,444,759 |
Zambia | $10,887,482 |
Nigeria | $10,240,580 |
Côte d'Ivoire | $9,891,355 |
Lesotho | $8,970,000 |
Eswatini | $8,755,038 |
Rwanda | $7,207,859 |
Zimbabwe | $6,531,917 |
Democratic Republic of the Congo | $4,885,157 |
Angola | $3,300,000 |
Namibia | $2,974,000 |
Vietnam | $1,690,324 |
Ghana | $1,180,000 |
Central Asia Region | $979,042 |
Central America Region | $963,226 |
Guyana | $933,453 |
Ukraine | $867,000 |
Dominican Republic | $775,000 |
India | $750,000 |
Caribbean Region | $600,000 |
South Sudan | $566,854 |
Burundi | $300,000 |
China | $50,000 |
Organizational Types
University | $430,446,343 |
Program Areas
Prevention | $133,779,004 |
Governance and Systems | $102,240,882 |
Treatment | $100,072,376 |
Care | $72,108,202 |
Testing | $22,245,879 |
Budget Codes
HTXS: Treatment: Adult Treatment | $84,436,457 |
OHSS: Health Systems Strengthening | $50,198,344 |
CIRC: Biomedical Prevention: Voluntary Medical Male Circumcision | $46,597,851 |
MTCT: Biomedical Prevention: Prevention of Mother to Child Transmission | $42,156,324 |
HVSI: Strategic Information | $36,753,770 |
HBHC: Care: Adult Care and Support | $27,423,336 |
HVOP: Sexual Prevention: Other Sexual Prevention | $25,311,740 |
HVTB: Care: TB/HIV | $23,719,369 |
HVCT: Testing: HIV Testing and Counseling | $22,245,879 |
PDTX: Treatment: Pediatric Treatment | $15,488,865 |
HLAB: Laboratory Infrastructure | $15,288,768 |
HKID: Care: Orphans and Vulnerable Children | $13,308,893 |
HVAB: Sexual Prevention: Abstinence/Be Faithful | $12,409,270 |
PDCS: Care: Pediatric Care and Support | $7,656,604 |
HMIN: Biomedical Prevention: Injection Safety | $4,087,105 |
IDUP: Prevention: Injecting and Non-Injecting Drug Use | $2,519,714 |
HMBL: Biomedical Prevention: Blood Safety | $697,000 |
HTXD: Treatment: ARV Drugs | $147,054 |